A study on over 15000 children in 7 African countries shows GlaxoSmithKline's anti-malaria vaccine halves the risk of contracting malaria. The trials were run on children between 6 and 12 weeks old, and between 5 and 17 months old.
Guardian article: http://www.guardian.co.uk/society/2011/oct/18/malaria-vaccine-save-millions-children
Full paper: http://www.nejm.org/doi/full/10.1056/NEJMoa1102287
From skimming the paper, this looks sound. GlaxoSmithKline both developed the vaccine and paid for the study, but that's standard. The disclosure forms don't show anything fishier.
There are ways this could go wrong. GlaxoSmithKline says they'll make it cheap (probably for PR) but this is not sufficient to ensure availability. This could also increase total risk by replacing bed nets, or by making other diseases worse.
Thoughts on the research? Comments on effects? Plans for wild celebration?